,

Rev Esp Quimioter 2022;35(Suppl.3):2-5

Vulnerability to SARS-CoV-2 infection and disease: ripping the curl after the storm

PABLO BARREIRO, JESÚS SAN ROMÁN ‎

Published: 24 October 2022

http://www.doi.org/10.37201/req/s03.01.2022

SARS-CoV-2 infection now seems to have entered the announced endemic phase. The population’s immunity is increasingly more robust, thanks to successive vaccination and booster campaigns, and the almost inevitable exposure and re-exposure to the virus itself, which has truly served as a natural immunizing mechanism. On the other hand, the genetic drift of the virus is leading it to become another catarrhal agent, as are the other endemic human coronaviruses. However, it should not be lost sight of that there are still segments of the population with susceptibility to severe COVID, who will be candidates to continue receiving vaccine boosters or antiviral drugs in the initial stages of infection.

Rev Esp Quimioter 2022; 35(Suppl.3):2-5 [Full-text PDF]


/por
,

Rev Esp Quimioter 2022; 35(6):579-580

Peritonitis por Clostridium baratii en paciente cirrótico

LAUDY RIVERO-RODRÍGUEZ, MARGARITA BOLAÑOS-RIVERO, JESÚS MANUEL RODRÍGUEZ DE LEÓN, ISABEL DE MIGUEL MARTÍNEZ

Published: 21 October 2022

LETTER TO THE EDITOR

http://www.doi.org/10.37201/req/051.2022

Rev Esp Quimioter 2022; 35(6):579-580  [Texto completo PDF]


/por
,

Rev Esp Quimioter 2022; 35(6):581-583

Micosis pulmonar crónica por Paracoccidioides brasiliensis

MARÍA ÁNGELES ASENCIO EGEA, JEAN CARLOS MÉNDEZ GONZÁLEZ, JORGE GAITÁN PITERA, JOSÉ MARÍA LÓPEZ-PINTOR HUERTAS, JAVIER SÁNCHEZ LÓPEZ, MARÍA HUERTAS VAQUERO

Published: 19 October 2022

LETTER TO THE EDITOR

http://www.doi.org/10.37201/req/057.2022

Rev Esp Quimioter 2022; 35(6):581-583  [Texto completo PDF]


/por
,

Rev Esp Quimioter 2022; 35(6):589-591

Nirmatrelvir/ritonavir as a potential treatment for prolonged SARS-CoV-2 infection in immunocompromised patients

IGNACIO PÉREZ CATALÁN, SERGIO GARCÍA MUÑOZ, CELIA ROIG MARTÍ, IRIS GÓMEZ ALFARO, LUIS SERRANO PICAZO, MIGUEL TORRES GARCÍA, ROBERTO REIG VALERO, RAÚL FERRANDO PIQUERES, LIDÓN MATEU CAMPOS, JOSÉ MANUEL RAMOS RINCÓN, JORGE USÓ BLASCO

Published: 18 October 2022

LETTER TO THE EDITOR

http://www.doi.org/10.37201/req/078.2022

Rev Esp Quimioter 2022; 35(6):589-591  [Texto completo PDF] [Full-text PDF]


/por
,

Rev Esp Quimioter 2022; 35(6):584-586

Cellulitis due to Pasteurella stomatis and Actinomyces canis following dog bite

DOMINGO FERNÁNDEZ-VECILLA, CRISTINA ASPICHUETA-VIVANCO, JOSÉ LUIS DÍAZ DE TUESTA-DEL ARCO

Published: 17 October 2022

LETTER TO THE EDITOR

http://www.doi.org/10.37201/req/067.2022

Rev Esp Quimioter 2022; 35(6):584-586  [Full-text PDF]


/por
,

Rev Esp Quimioter 2022; 35(6):566-569

Eumicetomas por Fusarium oxysporum y Madurella mycetomatis. Descripción de dos casos y revisión de la bibliografía

DIEGO MARTÍNEZ LÓPEZ, ANTONIO PÉREZ BLASCO, LUIS GARCÍA FERRER, JUAN J CAMARENA, ROSA GONZÁLEZ, JOSÉ LUIS RODRIGO PEREZ

Published: 17 October 2022

LETTER TO THE EDITOR

http://www.doi.org/10.37201/req/027.2022

Rev Esp Quimioter 2022; 35(6):566-569  [Texto completo PDF]


/por
,

Rev Esp Quimioter 2022; 35(6):544-550

Clinical characteristics and prognosis of Staphylococcus aureus bacteremia

ROSA GARCÍA FENOLL, MARÍA ESPINOSA PÉREZ, SARAY MORMENEO BAYO, VIOLETA FRUTOS MILLÁN, MARÍA CARMEN MARTÍNEZ JIMÉNEZ, ROSA MARÍA MARTÍNEZ ÁLVAREZ, MARÍA PILAR PALACIÁN RUIZ, MARÍA CRUZ VILLUENDAS USÓN, CARLOS RAMOS PAESA

Published: 7 October 2022

http://www.doi.org/10.37201/req/035.2022

Introduction. Staphylococcus aureus bacteremia patients characteristics at a tertiary hospital are described, and complications, mortality and associated factors are analyzed.
Methods. Data from patients with S. aureus bacteremia admitted between March 2020 and February2021 at Miguel Servet university hospital in Zaragoza were retrospectively analyzed.
Results. Results showed a 14 days mortality of 24.2% and an 30 days mortality of 40%. Overall survival decreased with complications appearance [HR 3.1 (1.2-8.05)] and age over 65 years [HR 3.1 (1.4-6.6)]. The adjusted analysis showed correlation between a higher mortality at 14 and 30 days with age over 65 years [OR 6.3 (1.7-23.1)], sepsis presence [OR 19.3 (5.4-68.7)] and number of positive (+) blood cultures ≥3 [OR 5.4 (0.8-34.1)]. Mortality at 14 days was associated with sepsis presence [OR 58.2 (5.7-592.9)], number of positive (+) blood cultures ≥3 [OR 14.1 (1.1-173.7)] and an older age [OR 1.1 (1.03-1.1)]. Analyzing time to positive blood cultures ≤12 hours and number of positive blood cultures ≥ 3 at the same time, frequency of sepsis increased [30 patients (66.6%) vs 15 patients (33.3%); OR 3.4 (IC95% 1.5-8)].
Conclusions. High 14- and 30-days mortality were found, as well as a worse evolution in older age patients, with sepsis presence, and with greater number of positive blood cultures and times to positive blood cultures ≤12 h.

Rev Esp Quimioter 2022; 35(6):544-550 [Texto completo PDF]


/por
,

Rev Esp Quimioter 2022;35(Suppl.2):45-47

Cefiderocol. Summary and conclusions

JOSÉ MENSA, JOSÉ BARBERÁN

Published: 4 October 2022

http://www.doi.org/10.37201/req/s02.07.2022

Rev Esp Quimioter 2022; 35(Suppl. 2):45-47 [Full-text PDF]


/por
,

Rev Esp Quimioter 2022;35(Suppl.2):39-44

The role of cefiderocol in clinical practice

EMILIO MASEDA, ALEJANDRO SUÁREZ DE LA RICA

Published: 4 October 2022

Cefiderocol is a new antimicrobial with a chemical structure similar to ceftazidime and cefepime. In this review we will focus on the role of cefiderocol in different clinical scenarios produced by resistant Gram-negative microorganisms, especially to carbapenems. In infections caused by Gram-negative microorganisms, inappropriate antibiotic treatment increased the risk of mortality almost fourfold.
In patients with hospital-acquired infection and septic shock; with sepsis and poor functional reserve due to fragility; in immunocompromised patients; and in those with local ecology, individual history of colonization or previous infection and risk factors for carbapenem-resistant Enterobacteriaceae (CRE) such as the presence of chronic multi-morbidities, the best option would be to start an active empirical treatment against gram-negative bacteria resistant to carbapenems and later in 24-36 h with the information obtained from the cultures we could decide on a definitive empirical or directed treatment and avoid unnecessary overuse of these antibiotics. Cefiderocol would be in these cases a good candidate due to its excellent in vitro activity against all classes of beta-lactamase-producing Gram-negatives (including carbapenemase class A, B and D producers), as well as against non-fermenting Gram-negatives such as P. aeruginosa, Acinetobacter spp. and S. maltophilia. It is necessary to optimize the use of new antibiotics such as cefiderocol, guaranteeing the best available treatment to patients while delaying the emergence and spread of resistance.

http://www.doi.org/10.37201/req/s02.06.2022

Rev Esp Quimioter 2022; 35(Suppl. 2):39-44 [Full-text PDF]


/por
,

Rev Esp Quimioter 2022;35(Suppl.2):35-38

Clinical experience of cefiderocol

MARÍA CARMEN FARIÑAS

Published: 4 October 2022

Infections by antibiotic-resistant microorganisms could be considered a “stealth pandemic” that we fight daily in most hospitals. Some estimates suggest that today 700,000 deaths per year can be attributed to antimicrobial resistance. By the year 2050, it is estimated that this will increase to ten million deaths per year as a result of infections by multidrug-resistant microorganisms. In this context, the availability of antimicrobial therapy that is effective against these pathogens is essential to be able to “save the lives” of our patients. Cefiderocol, a new cephalosporin with a different mechanism of action, will be an essential treatment in many infections caused by resistant aerobic gram-negative bacteria. Cefiderocol has been used to treat patients with complicated urinary tract infections (cUTI); hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP), healthcare-associated pneumonia (HAP); in patients with sepsis and bacteremia, some without an identified primary focus of infection.

http://www.doi.org/10.37201/req/s02.05.2022

Rev Esp Quimioter 2022; 35(Suppl. 2):35-38 [Full-text PDF]


/por